MEI Pharma Confirms Receipt of Director Nominations From Anson and Cable Car
18 Setembro 2023 - 9:00AM
Business Wire
No Stockholder Action Required at This Time
MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today issued the
following statement regarding the nomination of three director
candidates by Anson Advisors Inc. and Cable Car Capital LLC to
stand for election to the Company’s Board of Directors at MEI’s
fiscal year 2024 Annual Meeting of Stockholders.
MEI, a clinical development company dedicated
to bringing new treatments to patients with cancer, is nearing a
significant moment in the Company’s history. We are making
important progress advancing two promising clinical-stage pipeline
programs – voruciclib and ME-344 – and we have important inflection
points with readouts of clinical data expected during the first
half of 2024 from both of our programs. With the progression of our
development pipeline, promising early clinical data and capital to
support our near-term development plans, MEI is well positioned to
create value for stockholders and deliver improved therapeutic
options to patients.
MEI’s directors bring the skills, knowledge
and expertise necessary to provide strong oversight and guide both
the strategic and operational direction of the Company at this
critical time. The Company’s directors are industry leaders with
strong track records in life sciences, including at public
biotechnology and pharmaceutical companies, and have expertise
across medical and scientific, marketing, financial, governance,
legal and regulatory matters.
Over the last several months, Anson and Cable
Car have been running an opportunistic campaign to take control of
the Company without paying what the Board believes is an
appropriate premium to do so. It is clear from discussions members
of our Board and management team have had with Anson and Cable Car
during that time, that they have a single-minded agenda to obtain
the Company’s cash now without paying a premium, regardless of the
opportunity cost to the MEI’s development programs and other
stockholders.
The MEI Board will review the Anson and Cable
Car nominees in accordance with the Company’s corporate governance
guidelines and principles and its fiduciary duties to all
stockholders. The MEI Board of Directors and management team will
continue to take actions that it believes represent the best
interest of ALL MEI
stockholders.
The MEI Board will present its recommendation with respect to
the election of directors in the Company’s proxy statement, which
will be filed with the Securities and Exchange Commission and
mailed to all stockholders eligible to vote at the Company’s fiscal
year 2024 Annual Meeting of Stockholders.
MEI stockholders do not need to take any action at this
time.
About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a pharmaceutical company
focused on developing potential new therapies for cancer. MEI
Pharma’s portfolio of drug candidates includes clinical stage
candidates with differentiated mechanisms of action intended to
address unmet medical needs and deliver improved benefit to
patients, either as standalone treatments or in combination with
other therapeutic options. For more information, please visit
www.meipharma.com. Follow us on X (formerly Twitter) @MEI_Pharma
and on LinkedIn.
Important Information and Where to Find It:
This press release is neither a solicitation of a proxy or
consent nor a substitute for any proxy statement or other filings
that may be made with the Securities and Exchange Commission (the
“SEC”). Nonetheless, the Company, its directors and/or its director
nominees and certain of its executive officers and employees may be
deemed to be participants in the solicitation of proxies from the
Company’s stockholders in connection with the fiscal year 2024
Annual Meeting. The Company plans to file a proxy statement with
the SEC in connection with the solicitation of proxies for the
fiscal year 2024 Annual Meeting (the “Fiscal 2024 Proxy
Statement”).
STOCKHOLDERS ARE URGED TO READ THE FISCAL 2024 PROXY STATEMENT
(INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER
RELEVANT DOCUMENTS THAT THE COMPANY WILL FILE WITH THE SEC WHEN
THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION.
Additional information regarding the identity of these potential
participants and their direct or indirect interests, by security
holdings or otherwise, will be set forth in the Fiscal 2024 Proxy
Statement and other materials to be filed with the SEC in
connection with the fiscal year 2024 Annual Meeting. Such
information can also be found in the Company’s definitive proxy
statement for the fiscal year 2023 Annual Meeting of Stockholders,
filed with the SEC on October 27, 2022, the Company’s Annual Report
on Form 10-K for the fiscal year ended June 30, 2022, filed with
the SEC on September 8, 2022, and in the Company’s Current Reports
on Form 8-K filed with the SEC from time to time. To the extent
holdings of the Company’s securities have changed since the amounts
shown in the definitive proxy statement for the fiscal year 2023
Annual Meeting of Stockholders, such changes have been or will be
reflected on Initial Statements of Beneficial Ownership on Form 3
or Statements of Change in Ownership on Form 4 filed with the SEC.
Updated information regarding the identities of potential
participants and their direct or indirect interests, by security
holdings or otherwise, in the Company will be set forth in the
Fiscal 2024 Proxy Statement and other relevant documents to be
filed with the SEC, if and when they become available.
Stockholders will be able to obtain, free of charge, copies of
the Fiscal 2024 Proxy Statement (including any amendments or
supplements thereto) and any other documents filed by the Company
with the SEC in connection with the Fiscal 2024 Annual Meeting at
the SEC’s website (www.sec.gov) or the Company’s investor website
at https://www.meipharma.com/investors.
Forward-Looking Statements
Certain information contained in this press release that are not
historical in nature are "forward-looking statements" within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995 including, without limitation,
statements regarding: the director nominations discussed above, the
potential, safety, efficacy, and regulatory and clinical progress
of our product candidates, including the anticipated timing for
initiation of clinical trials and release of clinical trial data
and our expectations surrounding potential regulatory submissions,
approvals and timing thereof, our business strategy and plans; the
sufficiency of our cash, cash equivalents and short-term
investments to fund our operations. You should be aware that our
actual results could differ materially from those contained in the
forward-looking statements, which are based on management's current
expectations and are subject to a number of risks and
uncertainties, including, but not limited to our failure to
successfully commercialize our product candidates; the availability
or appropriateness of utilizing the FDA’s accelerated approval
pathway for our product candidates; final data from our
pre-clinical studies and completed clinical trials may differ
materially from reported interim data from ongoing studies and
trials; costs and delays in the development and/ or FDA approval,
or the failure to obtain such approval, of our product candidates;
uncertainties or differences in interpretation in clinical trial
results; uncertainty regarding the impact of rising inflation and
the increase in interest rates as a result; potential economic
downturn; activist investors; our inability to maintain or enter
into, and the risks resulting from, our dependence upon
collaboration or contractual arrangements necessary for the
development, manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our inability to
protect our patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property to operate
our business; our inability to operate our business without
infringing the patents and proprietary rights of others; general
economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required
financing; technological changes; government regulation; changes in
industry practice; and one-time events. We do not intend to update
any of these factors or to publicly announce the results of any
revisions to these forward-looking statements. Under U.S. law, a
new drug cannot be marketed until it has been investigated in
clinical studies and approved by the FDA as being safe and
effective for the intended use.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230917627079/en/
David A. Walsey 858-369-7104 investor@meipharma.com
Joele Frank, Wilkinson Brimmer Katcher Dan Katcher / Aaron
Palash 212-355-4449 MEIP-jf@joelefrank.com
MEI Pharma (NASDAQ:MEIP)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
MEI Pharma (NASDAQ:MEIP)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024